Provided by Tiger Trade Technology Pte. Ltd.

Compass Therapeutics, Inc.

0.9730
-0.0470-4.61%
Volume:4.94M
Turnover:4.83M
Market Cap:175.23M
PE:-2.41
High:1.01
Open:1.01
Low:0.9573
Close:1.02
52wk High:6.88
52wk Low:0.8294
Shares:180.09M
Float Shares:132.00M
Volume Ratio:0.46
T/O Rate:3.74%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4039
EPS(LYR):-0.4216
ROE:-56.66%
ROA:-33.03%
PB:1.06
PE(LYR):-2.31

Loading ...

Compass Therapeutics - to Further Engage with FDA on Bla Submission for Tovecimig

THOMSON REUTERS
·
Sep 22

Compass Therapeutics - Does not Believe New Trial is Warranted Before Bla Submission for Tovecimig

THOMSON REUTERS
·
Sep 22

Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback

THOMSON REUTERS
·
Sep 22

Compass Therapeutics - Remains Confident in Tovecimig Based on Significant Orr and Pfs Improvements

THOMSON REUTERS
·
Sep 22

Analyst Reiterates Buy on Compass Therapeutics Ahead of Key FDA Catalyst; $7 Price Target Maintained

TIPRANKS
·
Sep 01

Compass Therapeutics Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 10

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Aug 07

Analysts Offer Insights on Healthcare Companies: Compass Therapeutics (CMPX) and Halozyme (HALO)

TIPRANKS
·
Aug 07

Relay Therapeutics Q2 Revenue Misses Estimates on Higher R&D Expenses; Net Loss Widens

Reuters
·
Aug 07

Compass Therapeutics Q2 2026 earnings: Pipeline spending widens the net loss

TradingKey
·
Aug 06

CG Oncology Q2 Net Loss Widens on Higher R&D Costs

Reuters
·
Aug 06

Compass Therapeutics Q2 EPS $(0.13) Misses $(0.11) Estimate

Benzinga Earnings
·
Aug 06

Compass Therapeutics Q2 2026 Net Loss Widens 26.63% to $25.2 Million; R&D Expenses Rise 19% to $19.6 Million

Reuters
·
Aug 06

Compass Therapeutics: $180 Mln in Cash and Marketable Securities at End of Q2 2026, Which is Expected to Fund Operations into 2028

THOMSON REUTERS
·
Aug 06

Compass Therapeutics Q2 Income from Operations USD -26.979 Million

THOMSON REUTERS
·
Aug 06

Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update

GlobeNewswire
·
Aug 06

Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the Esmo Congress 2026

THOMSON REUTERS
·
Jul 17

Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026

GlobeNewswire
·
Jul 17

Compass Showcases Promising Tovecimig Data, Eyes Commercialization

TIPRANKS
·
Jul 02

Analysts Offer Insights on Healthcare Companies: Zimmer Biomet Holdings (ZBH), Compass Therapeutics (CMPX) and 10x Genomics (TXG)

TIPRANKS
·
Jul 01